Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

Deep sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia Running Title: Deep sequencing method for MRD detection

LYMPHOID NEOPLASIA Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphoblastic leukemia (ALL). We developed a high-throughput sequencing method that universally amplifies antigenreceptor gene segments and identifies all clonal gene rearrangements (ie, leukemiaspecific sequences) at diagnosis, allowing monitoring of disease progression and clon...

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphoblastic leukemia (ALL). We developed a high-throughput sequencing method that universally amplifies antigen-receptor gene segments and identifies all clonal gene rearrangements (ie, leukemia-specific sequences) at diagnosis, allowing monitoring of disease progression and cl...

Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

MRD diagnostics during the first three months of treatment has proven to be of high value in pediatric acute lymphoblastic leukemia (ALL), because of its potential to recognize subgroups that differ substantially in outcome. Consequently, MRD diagnostics is now being used for treatment intervention, both treatment intensification (including stem cell transplantation) and treatment reduction. Ho...

Detection of minimal residual disease in acute lymphoblastic leukemia.

To detect more precisely the minimal residual disease in acute lymphoblastic leukemia (ALL), two-color flow cytometric analysis for the detection of cell-surface antigen (CD10; CALLA) and nuclear terminal deoxynucleotidyl transferase (TdT) was performed in the six patients with CALLA-positive ALL coexpressing TdT. In all patients, the leukemic blasts coexpressed Ia (HLA-DR), CD9, CD19, CD20, CD...